EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Disease characteries, treatment patterns, and oncological outcomes of de novo metastatic hormone-sensitive prostate cancer: real-world experience from a multicenter Asian cohort

Ivan Ching-Ho Ko, Kevin Cheuk Kin Cheng, Chris Ho-Ming Wong, Joycelyn Yung Yung Lim, Candice Hiu Tung Mok, Cheuk Yi Tang, Brian Chun Fai Kwok, Yi-Hong Zhou, Chi Ho Leung, Peggy Sau Kwan Chu, Joseph Kai Man Li, Chi Fai Ng

Asian Journal of Andrology · 2026-11 · 28 (6) · 766-772

DOI: 10.4103/aja202616 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Asian Journal of Andrology, online erschienen am 14.07.2026. Verfasst von Ivan Ching-Ho Ko und 11 weiteren Autor:innen. Beteiligte Einrichtung: SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Androgen Antagonists, Prostatic Neoplasms, Androgen Receptor Antagonists, Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This multicenter retrospective study assessed real-world treatment patterns and outcomes in de novo metastatic hormone-sensitive prostate cancer (mHSPC) across five urological centers in Hong Kong (China; from 2016 to 2023). Of 3308 patients, 814 (24.6%) presented with de novo mHSPC. High-volume and high-risk disease were present in 59.1% and 53.8% of patients, respectively. Despite guidelines favoring intensified therapy, androgen deprivation therapy (ADT) monotherapy remained the most common treatment (52.0%), while only 28.7% received upfront chemotherapy (20.5%) or androgen receptor pathway inhibitors (ARPI; 8.2%). During a median 40-month follow-up period, 48.4% of patients died and 60.1% progressed to castration-resistant prostate cancer (CRPC) within a median of 19 months. Five-year overall survival rates were highest for ARPI (64.9%), followed by chemotherapy (53.5%) and monotherapy (38.7%), with corresponding 5-year CRPC-free survival rates of 73.5%, 7.7%, and 15.0%, respectively. Upfront chemotherapy and ARPI demonstrated significant reductions in cancer-specific mortality compared to ADT monotherapy (chemotherapy hazard ratio [HR]: 0.58, 95% confidence interval [CI]: 0.41–0.82, P = 0.002; ARPI HR: 0.32, 95% CI: 0.17–0.62, P < 0.001). High-volume disease (HR: 2.14, 95% CI: 1.52–3.01, P < 0.001) and ISUP Grade 4 or 5 (HR: 5.70, 95% CI: 1.82–17.87, P = 0.003) conferred increased risk. Upfront chemotherapy and ARPI were independently associated with improved overall survival (chemotherapy HR: 0.56, 95% CI: 0.41–0.78, P < 0.001; ARPI HR: 0.41, 95% CI: 0.24–0.69, P < 0.001). High-volume mHSPC (HR: 1.65, 95% CI: 1.24–2.21, P < 0.001) and ISUP Grade 4 or 5 (HR: 2.38, 95% CI: 1.22–4.65, P = 0.011) were significant adverse prognostic factors. Advanced age at diagnosis was associated with increased all-cause mortality (HR: 1.02, 95% CI: 1.00–1.03, P = 0.037). These findings highlight an urgent need to improve adoption of intensified treatment strategies for optimal patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsProstatic NeoplasmsAndrogen Receptor AntagonistsProstatic Neoplasms, Castration-ResistantMaleHumansRetrospective StudiesAgedHong KongMiddle AgedTreatment OutcomeNeoplasm Metastasis

Stichwörter der Autor:innen

androgen antagonistsandrogen receptor antagonistscastration-resistant prostatic neoplasmsneoplasm metastasisprostatic neoplasms

Substanzen

Androgen AntagonistsAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Department of Surgery, Prince of Wales Hospital, Hong Kong SAR, China.
  • Department of Surgery, Tuen Mun Hospital, Hong Kong SAR, China.
  • Department of Surgery, Pok Oi Hospital, Hong Kong SAR, China.
  • Department of Surgery, North District Hospital, Hong Kong SAR, China.

Zitieren

APA

Ko, I. C., Cheng, K. C. K., Wong, C. H., Lim, J. Y. Y., Mok, C. H. T., Tang, C. Y., Kwok, B. C. F., Zhou, Y. H., Leung, C. H., Chu, P. S. K., Li, J. K. M., & Ng, C. F. (2026). Disease characteries, treatment patterns, and oncological outcomes of de novo metastatic hormone-sensitive prostate cancer: real-world experience from a multicenter Asian cohort. Asian Journal of Andrology, 28(6), 766-772. https://doi.org/10.4103/aja202616

Vancouver

Ko IC, Cheng KCK, Wong CH, Lim JYY, Mok CHT, Tang CY, et al. Disease characteries, treatment patterns, and oncological outcomes of de novo metastatic hormone-sensitive prostate cancer: real-world experience from a multicenter Asian cohort. Asian Journal of Andrology. 2026;28(6):766-772. doi:10.4103/aja202616

BibTeX
@article{Ko2026,
  author = {Ko, Ivan Ching-Ho and Cheng, Kevin Cheuk Kin and Wong, Chris Ho-Ming and Lim, Joycelyn Yung Yung and Mok, Candice Hiu Tung and Tang, Cheuk Yi and Kwok, Brian Chun Fai and Zhou, Yi-Hong and Leung, Chi Ho and Chu, Peggy Sau Kwan and Li, Joseph Kai Man and Ng, Chi Fai},
  title = {Disease characteries, treatment patterns, and oncological outcomes of de novo metastatic hormone-sensitive prostate cancer: real-world experience from a multicenter Asian cohort},
  journal = {Asian Journal of Andrology},
  year = {2026},
  volume = {28},
  number = {6},
  pages = {766--772},
  doi = {10.4103/aja202616}
}
Kostenlos starten →